Adaptive Biotechnologies News and Activities
Presence
Adaptive Biotechnologies is a biotechnology company that leverages advanced sequencing and bioinformatics to develop immune-driven medicine. Their offerings are designed to address the needs of researchers, clinicians, and pharmaceutical companies by providing insights into the adaptive immune system.
Adaptive Biotechnologies products and services overview:
- ImmunoSEQ
- clonoSEQ
- T-Detect
Employees: 600
Adaptive Biotechnologies is one of the...
Adaptive Biotechnologies is a company listed under the stock ticker ADPT (US).
Executives
View the org chart displaying its 17 main executives
Most searched biographies at Adaptive Biotechnologies
- Chad Robins, President, Chief Executive Officer and Director
- Mike Pellini, Director
- Robert Hershberg, Director
Popular executive movements at Adaptive Biotechnologies
- Stacy Taylor, Senior Vice President and General Counsel, is retiring (posted on February 24 2025).
Create your alert
to follow the executive moves at Adaptive Biotechnologies.
Biotechnology
Adaptive Biotechnologies has 2,350 competitors including Astellas Gene Therapies (United States (USA)), Eurofins (Luxembourg) and BitBiome (United States (USA)).
Popular M&A news in Biotechnology
- Actio Biosciences has just announced a $66 Million fundraising (posted on June 19 2025).
- Prenetics has just announced a $20 Million fundraising (posted on June 19 2025).
- Draig Therapeutics has just announced a $140 Million fundraising (posted on June 18 2025).
Popular contacts in Biotechnology
News
Press releases by Adaptive Biotechnologies
- Events - Adaptive Biotechnologies
- Adaptive Biotechnologies to Report Third Quarter Financial Results on November 10, 2020 - Adaptive Biotechnologies
- Adaptive Biotechnologies to Present at the Morgan Stanley 2020 Healthcare Conference - Adaptive Biotechnologies
- Press Releases - Adaptive Biotechnologies
- Adaptive Biotechnologies Reports Second Quarter 2020 Financial Results - Adaptive Biotechnologies
- Adaptive Biotechnologies to Present at the UBS Genomics 2.0 and Medtech Innovations Summit - Adaptive Biotechnologies
- Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal Residual Disease (MRD) in Patients with Chronic Lymphocytic Leukemia - Adaptive Biotechnologies
- Adaptive Biotechnologies Launches immunoSEQ T-MAP COVID, First Molecular T Cell Monitoring Tool for SARS-CoV-2 - Adaptive Biotechnologies
- Adaptive Biotechnologies Launches National Clinical Trial to Develop Novel T-Cell Based Diagnostic for Lyme Disease - Adaptive Biotechnologies
- Adaptive Biotechnologies Announces Pricing of Public Offering of Common Stock - Adaptive Biotechnologies
- View more press releases Close
Social media about Adaptive Biotechnologies
- Adaptive Biotechnologies on Wikipedia, Google News & Yahoo Finance
- Adaptive Biotechnologies on LinkedIn, Twitter & YouTube
